Get the Stockscreener App
14.20
6.61%
0.88
After Hours:
14.24
0.04
+0.28%
Hutchmed China Limited Adr stock is traded at $14.20, with a volume of 106.10K.
It is up +6.61% in the last 24 hours and down -4.44% over the past month.
HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.
See More
Previous Close:
$13.32
Open:
$13.99
24h Volume:
106.10K
Relative Volume:
1.31
Market Cap:
$2.43B
Revenue:
$420.26M
Net Income/Loss:
$-41.97M
P/E Ratio:
-56.80
EPS:
-0.25
Net Cash Flow:
$-65.34M
1W Performance:
-5.52%
1M Performance:
-4.44%
6M Performance:
-25.77%
1Y Performance:
-5.52%
1-Day Range:
$13.79
$14.32
1-Week Range:
$13.00
$15.29
52-Week Range:
$11.93
$21.92
Hutchmed China Limited Adr Stock (HCM) Company Profile
Compare HCM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HCM
Hutchmed China Limited Adr
|
14.20 | 2.43B | 420.26M | -41.97M | -65.34M | -0.25 |
|
ZTS
Zoetis Inc
|
165.89 | 74.84B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.24 | 41.78B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
12.92 | 40.96B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
21.92 | 24.83B | 16.77B | -959.00M | 1.37B | -0.85 |
|
NBIX
Neurocrine Biosciences Inc
|
143.26 | 14.50B | 2.24B | 385.90M | 440.10M | 3.73 |
Hutchmed China Limited Adr Stock (HCM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-24-23 | Upgrade | Deutsche Bank | Hold → Buy |
| May-04-22 | Downgrade | Deutsche Bank | Buy → Hold |
| Sep-22-21 | Downgrade | Goldman | Buy → Neutral |
| Aug-03-21 | Initiated | Jefferies | Buy |
| Oct-02-20 | Initiated | Deutsche Bank | Buy |
| Mar-13-20 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-20-20 | Initiated | Goldman | Buy |
| Nov-19-19 | Initiated | CLSA | Buy |
| Oct-23-19 | Reiterated | BofA/Merrill | Buy |
| Jul-05-19 | Initiated | Macquarie | Outperform |
View All
Hutchmed China Limited Adr Stock (HCM) Latest News
Private equity firms are HUTCHMED (China) Limited's (LON:HCM) biggest owners and were rewarded after market cap rose by UK£120m last week - Yahoo Finance
Hutchmed announces progress, hits milestone with lung cancer treatment - ShareCast
Market news - Research the market
Chinese Cancer Drug Developer Hutchmed Sharpens R&D Focus, Divests Non-Core JV For Over $600 Million - Benzinga
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy - The Manila Times
HUTCHMED Announces NDA Acceptance in China with Priority - GlobeNewswire
Jane Street Group LLC Raises Stock Holdings in HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World
HUTCHMED (China) Limited (NASDAQ:HCM) Shares Purchased by State Street Corp - Defense World
HCMHUTCHMED (China) Limited American Depositary Shares Latest Stock News & Market Updates - StockTitan
HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy - The Manila Times
HUTCHMED Announces Breakthrough Therapy Designation in - GlobeNewswire
HUTCHMEDNew sovleplenib clinical data showcased at ASH - Research Tree
Hutchmed endometrial cancer treatment gets conditional approval in China - ShareCast
M&G Plc Has $5.35 Million Holdings in HUTCHMED (China) Limited (NASDAQ:HCM) - MarketBeat
How Trump and Harris plan to address housing affordability - Yahoo Finance
Blue Trust Inc. Purchases 3,057 Shares of HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World
HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial - Yahoo Finance
HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful - The Bakersfield Californian
HUTCHMED (China) Ltd (HCM) (Q2 2024) Earnings Call Highlights: Strong US Sales Propel Growth ... - Yahoo Finance
FDA Approves 16 New Cancer Treatments As Global Cancer Rates Skyrocket - Barchart
Vanguard Personalized Indexing Management LLC Buys 1,168 Shares of HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World
Rhumbline Advisers Boosts Stock Position in HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World
Research Analysts Set Expectations for HUTCHMED (China) Limited’s FY2025 Earnings (NASDAQ:HCM) - Defense World
HUTCHMED (LON:HCM) Share Price Crosses Above 200 Day Moving Average of $284.47 - Defense World
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing - The Manila Times
HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda - Yahoo Finance
CN National Reimbursement Drug List Raises Requirements on Innovative Drugs: Report - AASTOCKS.com
International companies to host live webcasts at Deutsche - GlobeNewswire
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024 - Yahoo Finance UK
International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024 - Kirkland Lake Northern News
HUTCHMED (China) Limited (NASDAQ:HCM) Shares Sold by Acadian Asset Management LLC - Defense World
HUTCHMED (LON:HCM) Stock Price Crosses Below 200 Day Moving Average of $283.02 - Defense World
HUTCHMED (LON:HCM) Stock Crosses Below 200 Day Moving Average of $281.77 - Defense World
7 Best-Performing China Stocks for October 2024 - NerdWallet
HUTCHMED Voluntarily Withdraws Supplemental New Drug Application in China for Fruquintinib - AASTOCKS.com
HUTCHMED (LON:HCM) Stock Crosses Below Two Hundred Day Moving Average of $280.85 - Defense World
VP Kamala Harris to address Americans at DNC: What to expect - Yahoo Finance
LOBO EV Launches Innovative Solar-Powered Golf Cart to Address Increasing Market Demand for Sustainable Transportation Solutions - Yahoo Finance
HUTCHMED (China) Limited (NASDAQ:HCM) Sees Large Drop in Short Interest - Defense World
HUTCHMED (LON:HCM) Share Price Crosses Above 200-Day Moving Average of $277.00 - Defense World
XPeng Inc. Sponsored ADR (XPEV) Laps the Stock Market: Here's Why - Yahoo Finance
Here is What to Know Beyond Why PDD Holdings Inc. Sponsored ADR (PDD) is a Trending Stock - Yahoo Finance
What Starbucks' new CEO must instantly do to address crisis - Yahoo Finance
Sea Limited (SE) Q2 Earnings Miss Estimates, Revenues Up Y/Y - Yahoo Finance
Here's Why PDD Holdings Inc. Sponsored ADR (PDD) Gained But Lagged the Market Today - Yahoo Finance
Sea Limited (SE) Reportedly Hikes Merchant Fees to Boost Profit - Yahoo Finance
Contrast Security Application Detection and Response (ADR) Praised by Industry Analysts for Addressing Gap in Cybersecurity Defenses - Yahoo Finance
Global Industrial Introduces GlobalPure(TM) PFAS Water Filter to Address Forever Chemicals and Microplastics in Drinking Water - Yahoo Finance
MINISO Group Holding Limited Unsponsored ADR (MNSO) Trades Flat On The Day: What You Should Know - Yahoo Finance
InventHelp Inventor Develops Improved Address Display (CHK-1079) - Yahoo Finance
Sea Limited (SE) to Post Q2 Earnings: What's in the Cards? - Yahoo Finance
Hutchmed China Limited Adr Stock (HCM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
0.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):